TCRX Stock Analysis: Buy, Sell, or Hold?
TCRX - TScan Therapeutics, Inc. Common Stock
$0.74
-0.01 (-1.68%)
▼
5d:
-6.42%
30d:
-30.56%
90d:
-35.95%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
7d
Get Alerted When TCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TCRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TCRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TCRX is currently trading at $0.74, which is considered oversold relative to its 30-day fair value range of $0.85 to $1.06.
Technical Outlook: Technically, TCRX is in a downtrend. The price is currently testing key support at $0.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TCRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.00 (+707.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TCRX is in a downtrend. The price is currently testing key support at $0.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TCRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.00 (+707.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.85 -
$1.06
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 707.5% below Wall St target ($6.00)
- CAUTION: 5-day price weakness (-6.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.85 -
$1.06
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.73
Resistance Level
$0.97
Current Trend
Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.84
Wall Street Target
$6.00
(+707.5%)
Revenue Growth (YoY)
-54.8%
Share & Embed Analysis
Last updated: August 02, 2026 11:00 PM ET
Data refreshes hourly during market hours. Next update: 12:00 AM
Data refreshes hourly during market hours. Next update: 12:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
